INCY vs SLN
Incyte vs Silence Therapeutics plc — AI-powered side-by-side comparison
VS
SLN
Silence Therapeutics plc
48
Watch
| Metric | INCY | SLN |
|---|
| AI Score |
72
|
48
|
| Price |
$121.08
|
$14.69
|
| P/E Ratio |
14.89×
|
-6.72×
|
| ROE |
24.9%
|
-142.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
68.6%
|
| Debt / Equity |
0.01×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.2
|
74.4
|
| Beta |
0.769
|
1.351
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus SLN.
INCY leads by 24 points.
INCY scores 72/100 (Buy) versus SLN at 48/100 (Watch).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
SLN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -99.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -103.3% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.02 adds balance-sheet risk to the value case — Value
- Revenue declining -99.3% YoY -- this is not a growth story right now — Growth